Alpha Receptor Agonist Toxicity

Alpha Receptor Agonist Toxicity

Credits: 1.00   Post-Assessment Questions:  4

Release Date: 5 Oct 2020
Expiration Date: 15 Aug 2021
Last Reviewed: 15 Aug 2020
Estimated Time To Finish: 60 Minutes

Need Help?  If you have a system or content concerns, please contact support@statpearls.com, or call (727) 289-9796.

Activity Description

Alpha-adrenergic agonist toxicity is due to a broad group of pharmaceutical agents known as alpha agonists, which can be further broken down into central alpha-2 agonists and peripheral alpha-1 agonists. Stimulation of central alpha-2 receptors causes decreased secretion of catecholamines through a negative feedback mechanism. Stimulation of peripheral alpha-1 receptors primarily increases blood pressure via induced vasoconstriction. Alpha-adrenergic agonist toxicity is of primary concern with alpha-2 adrenergic agonist xenobiotics through the resulting depletion of catecholamines associated with these agents; however, there are many topical alpha-1 agonists that when misused cause similar toxicity. This activity illustrates the pathophysiology and typical presentation of alpha-adrenergic agonist toxicity and discusses the role of the interprofessional team in evaluating and managing the condition to achieve better clinical outcomes.

Target Audience

This activity has been designed to meet the educational needs of physicians.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

• Review the pharmacology of alpha adrenergic agonists and the pathophysiology of alpha agonist toxicity.
• Identify the etiology and clinical presentation of alpha-adrenergic agonist toxicity.
• Summarize the the importance of initiating early symptomatic management in patients with alpha-adrenergic agonist toxicity,

Author(s) / Contributors Disclosure of Conflicts of Interest

Each author, editor, faculty and planning committee member have completed a disclosure form indicating that neither they nor their spouse/partner has a financial interest/arrangement or affiliation that could be perceived as a real or apparent conflict of interest related to the content of this activity.

COMMERCIAL SUPPORT: This activity has received NO commercial support.

Contributors

Hover over the contributor names to see details and disclosures of any financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

Authors: Kenneth Norman
Editors: Thomas Nappe
Editors-In-Chief: Alan HeffnerSusan MurinChristian Sandrock
Chief Medical Reviewer: B. Zane Horowitz
Nurse Planner/Reviewer/Editor: Lisa Haddad
Nurse Planner/Reviewer/Editor: Bernadette Makar
Nurse Planner/Reviewer/Editor: Dorothy Caputo
Pharmacy Planner/Reviewer/Editor: Mark Pellegrini
Physician Planner/Reviewer/Editor: Scott Dulebohn

Continuing Education Accreditation Information

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Quillen College of Medicine, East Tennessee State University, and StatPearls, LLC. The Quillen College of Medicine, East Tennessee State University is accredited by the ACCME to provide continuing medical education for physicians.

Quillen College of Medicine, East Tennessee State University designates this activity for a maximum of 1.00 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Cancellation Policy: Cancellations must be received in writing and a money-back guarantee is provided if not completely satisfied.

• StatPearls and ETSU reserve the right to cancel any course due to unforeseen circumstances. StatPearls and ETSU will not be responsible for other expenses incurred by the participant in the unlikely event that the program is canceled.

Equal Opportunity

• StatPearls and ETSU are Equal Opportunity / Affirmative Action / Equal Access Institutions. 

Medium or Media Used:

• Computer Requirements:  Internet Access
• E-mail Address

Instructions for Credit

1. Register for the activity and create a StatPearls login.     
2. Review the required accreditation information:  Target audience, learning objectives, and disclosure information.
3. Complete the entire self-study activity.
4. Complete the post-test assessments.
5. Successfully pass the post-test with a minimum score of 100%.
6. Complete the evaluation form.
7. Obtain a certificate.

StatPearls and ETSU adhere to ACCME Standards regarding commercial support of continuing medical education. It is the policy of StatPearls and ETSU that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that authors and editors will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation. Detailed disclosure will be made prior to starting the activity.

The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

• If you need help with the system or have a question about content, please contact support@statpearls.com, or call 727-289-9796.
• If you have a question about the ETSU CME providership, please contact wolfes1@etsu.edu.

Media Usage Rights

The contributors and editors of StatPearls have attested that all associated media (images and video) have been legally cleared for use with this activity.  All copyrights are reserved.

• Name: 'alpha agonist table.png' Attribution: Contributed by Kenneth Norman, MD